Michael McFadden is the CEO of Alpha Cognition, a biopharmaceutical company focused on developing novel therapeutics for debilitating neurodegenerative.
Michael McFadden is the CEO of Alpha Cognition, a biopharmaceutical company focused on developing novel therapeutics for debilitating neurodegenerative disorders. He was appointed CEO in April 2021. The company is preparing for the Q1 2025 launch of ZUNVEYL in the U.S. market. Prior to Alpha Cognition, he served as Chief Commercial Officer of MPower Health and held executive roles at Urovant Sciences and Avanir Pharmaceuticals.
Full founder directory · Investor directory · Company funding database · Fundraising library